{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', '7.5.6.2.', 'Eliciting and Recording Adverse Events', 'Eliciting Adverse Events', 'The patient should be asked about medically relevant changes in his health since the last visit,', 'with attention to any signs and symptoms that could be consistent with thrombosis. The patient', 'should also be asked if he has been hospitalized, had any accidents, used any new medications,', 'or changed concomitant medication routines (both prescription and OTC). In addition to patient', 'observations, AEs will be documented from any clinically relevant laboratory findings, physical', 'examination findings, ECG changes, or other findings that are relevant to patient safety.', 'Recording Adverse Events', 'The Investigator is responsible for recording non-serious AEs and SAEs that are observed or', 'reported by the patient after the time when the informed consent is signed regardless of their', 'relationship to IMP through the end of study. Non-serious AEs will be followed until the end of', 'study. SAEs will be followed until satisfactory resolution, until baseline level is reached, or until', 'the SAE is considered by the Investigator to be chronic or the patient is stable, as appropriate.', 'All AEs must be recorded in the source records for the clinical study center and in the eCRF for', 'the patient, whether or not they are considered to be drug-related. Each AE must be described in', 'detail: onset time and date, description of event, severity, relationship to investigational drug,', 'action taken, and outcome (including time and date of resolution, if applicable).', 'For SAEs, record the event(s) on both the eCRF and the SAE form.', 'For AEs that are considered AESI (Section 7.5.6.1), the Sponsor or its designee should be', 'notified within 24 hours using a supplemental AESI eCRF. Additional clinical and laboratory', 'information may be collected; see Section 6.2.3.1 regarding monitoring for liver abnormalities.', 'Refer to the eCRF completion guidelines for details on reporting events in the supplemental', 'AESI eCRF.', 'Since bleeding episodes are recorded as an efficacy assessment of fitusiran, these will not be', 'treated as AEs unless they meet any of the SAE criteria listed in Section 7.5.6.1. The', 'manifestation and frequency of bleeding episodes is an efficacy indicator of this study and ABR', 'is the focus of the primary and secondary efficacy analyses.', 'Recording an ISR', 'For all ISRs, the Investigator, or delegate, should submit a supplemental ISR eCRF, recording', 'additional information (eg, descriptions, onset and resolution date, severity, treatment given,', 'event outcome). An ISR is defined as a local reaction at or near the site of injection. \"At or', 'near\" the injection site includes reactions at the injection site, adjacent to the injection site, or a', 'reaction which may shift slightly away from the injection site due to gravity (eg, as may occur', 'with swelling or hematoma). Reactions with onset and resolution within 4 hours of the injection', '(eg, transient pain/burning at injection site) do not meet the study definition of ISRs, unless', 'immediate treatment is required. A systemic reaction which includes the injection site, eg,', 'generalized urticaria, other distinct entities or conditions like lymphadenopathy that may be near', 'the injection site, is not considered an ISR.', 'Property of the Sanofi Group - strictly confidential', '63']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', '7.5.6.3.', 'Serious Adverse Events and Adverse Events of Special Interest Require', 'Immediate Reporting to Sponsor/Designee', 'An assessment of the seriousness of each AE will be made by the Investigator. Any AE and', 'laboratory abnormality that meets the SAE criteria in Section 7.5.6.1 and any AESI must be', 'reported to the Sponsor or designee within 24 hours from the time that clinical study center staff', 'first learns of the event. All SAEs must be reported regardless of the relationship to IMP.', 'The initial report should include at least the following information:', \"Patient's study number\", 'Description and date of onset of the event', 'Criterion for serious', 'Preliminary assignment of relationship to IMP, and', 'Investigator/site information', 'To report the SAE, complete the SAE form. Within 24 hours of receipt of follow-up', 'information, the Investigator must update the SAE form. SAEs must be reported using the', 'contact information provided in the Study Manual.', 'Appropriate remedial measures should be taken by the Investigator using his/her best medical', \"judgment to treat the SAE. These measures and the patient's response to these measures should\", 'be recorded. All SAEs, regardless of relationship to IMP, will be followed by the Investigator', 'until satisfactory resolution or the Investigator deems the SAE to be chronic or stable. Clinical,', 'laboratory, and diagnostic measures should be employed by the Investigator as needed to', 'adequately determine the etiology of the event.', '7.5.6.4.', 'Sponsor Safety Reporting to Regulatory Authorities', 'The Sponsor or its representative will report certain study events in an expedited manner to the', \"Food and Drug Administration, the European Medicines Agency's EudraVigilance electronic\", 'system according to Directive 2001/20/EC, and to all country Regulatory Authorities where the', 'study is being conducted, according to local applicable regulations.', '7.5.6.5.', 'Serious Adverse Event Notification to the Institutional Review', 'Board/Independent Ethics Committee', 'Suspected unexpected serious adverse reactions (SUSARs) will be reported to the IRB/IEC per', 'their institutional policy by the Investigator or Sponsor (or Sponsor designee) according to', 'country requirements. Copies of each report and documentation of IRB/IEC notification and', \"acknowledgement of receipt will be kept in the Investigator's study file.\", '7.5.6.6.', 'Pregnancy Reporting', 'There will only be male patients in this study.', 'The reporting of any pregnancy outcome for a female partner of a male patient participating in', 'this study that results in a postpartum complication, spontaneous abortion, stillbirth, neonatal', 'death, or congenital anomaly should be reported to the Investigator, who will then report this to', 'Property of the Sanofi Group - strictly confidential', '64']\n\n###\n\n", "completion": "END"}